The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million.
GW Pharma trades on the Nasdaq under the ticker symbol GWPH.
Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement
Latest Headlines
- Arkansas reaches $187 million in medical cannabis sales
- VA recreational marijuana market would need 5 years to mature, report says
- New Jersey court tosses medical cannabis licensing issue back to state
- Georgia taking applications to produce ‘low-THC’ marijuana oil
- Cannabis SPAC acquires Caliva and Left Coast Ventures, hires Jay-Z
- Zenabis selling cannabis facility for half original asking price
- Aurora Cannabis shuts CA$250 million greenhouse ‘indefinitely’
- Netherlands to draw 10 recreational marijuana growers this week
- Canadian cannabis firm Organigram reports CA$136M loss for year
- Cannabis NB expects CA$10M profit; privatization update ‘in near future’
